<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04770974</url>
  </required_header>
  <id_info>
    <org_study_id>17852_bio</org_study_id>
    <nct_id>NCT04770974</nct_id>
  </id_info>
  <brief_title>Urothelial Cancer Tumor Bio-markers and Physical-spectroscopic Characteristic</brief_title>
  <official_title>Definition of Tumor Bio-markers and Physical-spectroscopic Differences Between Healthy Urothelial Tissue Healthy and Urothelial Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florence</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Milano Bicocca</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fondazione C.N.R./Regione Toscana &quot;G. Monasterio&quot;, Pisa, Italy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Careggi Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Florence</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our multicenter observational study is a non-profit prospective study. The study was born&#xD;
      from the Amplitude Project, which comprise the SOD of Minimally Invasive Robotic Urological&#xD;
      Surgery and Renal Transplants of AOU Careggi with the University of Florence, as well as with&#xD;
      the National Research Council (CNR) and the University of Milan Bicocca (UNIMIB) The study&#xD;
      consists of a phase of enrollment of patients who will be admitted to the SOD of Mini&#xD;
      Invasive Robotic Urological Surgery and Renal Transplantation of AOU Careggi. Enrollment in&#xD;
      the study does not alter normal clinical practice and does not involve additional risks for&#xD;
      patients. Patients will have to meet the inclusion and exclusion criteria of the study and&#xD;
      will be enrolled sequentially, until the established sample size is reached. Patients&#xD;
      undergoing surgery for the removal of bladder neoplasm, be it endoscopic or surgical with&#xD;
      radical intent (cystectomy), will be taken a fragment of tumor bladder tissue, on which&#xD;
      histopathological analysis will be performed. In patients undergoing radical cystectomy only,&#xD;
      a fragment of healthy urothelial tissue, free from neoplasia, will also be removed. The&#xD;
      samples will be performed in patients under general and / or spinal anesthesia in case of&#xD;
      TURB, thus not causing pain or discomfort to the patient, or ex-vivo on the operative piece&#xD;
      in case of radical cystectomy, without causing further damage or pain to the patient. From&#xD;
      these samples, specially stored in solutions that keep their characteristics unaltered, a 3D&#xD;
      culture model (organoid) will be obtained both from cells obtained from bladder cancer and&#xD;
      from healthy tissue on which biomolecular, metabolomic and spectroscopic characterization&#xD;
      studies will be tested and carried out. with a view to staging and grading bladder neoplasia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 10, 2020</start_date>
  <completion_date type="Anticipated">July 7, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 7, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Metabolomic</measure>
    <time_frame>Enrollment</time_frame>
    <description>Metabolomic characteristic of bladder cancer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Spectroscopy</measure>
    <time_frame>Enrollment</time_frame>
    <description>Spectroscopical characteristic of bladder cancer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression</measure>
    <time_frame>Seven years</time_frame>
    <description>Comparison between different progression pattern among bladder cancer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response to treatments</measure>
    <time_frame>Seven years</time_frame>
    <description>Comparison between different treatment response pattern among bladder cancer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>Seven years</time_frame>
    <description>Comparison between different survival outcomes among bladder cancer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transcriptomic</measure>
    <time_frame>Enrollment</time_frame>
    <description>Transcriptomic characteristic of bladder cancer</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Urothelial Carcinoma</condition>
  <condition>Bladder Cancer</condition>
  <condition>Urothelial Neoplasm</condition>
  <condition>Urothelial Carcinoma Bladder</condition>
  <condition>Urothelial Carcinoma in Situ</condition>
  <arm_group>
    <arm_group_label>Urothelial Carcinoma</arm_group_label>
    <description>Patients over the age of 18 known for urological interventions for the following pathologies will be considered for enrollment in the group of cases:&#xD;
- Bladder cancer&#xD;
The exclusion criteria will be:&#xD;
Age under 18&#xD;
Pregnancy&#xD;
Lack of informed consent&#xD;
Inability to provide informed consent&#xD;
Patients included in the study, who meet the inclusion criteria, have an operative note for:&#xD;
Transurethral Resection of Bladder Neoplasia (TURBT)&#xD;
Radical Cystectomy for Bladder Neoplasia</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Biomarkers and proteomics</intervention_name>
    <description>Biomolecular, proteomic, metabolomic and spectroscopy characterization of urothelial bladder neoplasia, on a 3D culture model (organoid) obtained from bladder tumor tissue</description>
    <arm_group_label>Urothelial Carcinoma</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who will undergo a surgical intervention for bladder cancer will be enrolled&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age&gt;18 years&#xD;
&#xD;
          -  Bladder Cancer diagnosis&#xD;
&#xD;
          -  Capability to express informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age under 18&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Lack of informed consent&#xD;
&#xD;
          -  Inability to provide informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sergio Serni, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florence</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mauro Gacci, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AOU Careggi</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Simone Morselli, MD</last_name>
    <phone>3473050852</phone>
    <email>simone.morselli@unifi.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Silvia Benemei, MD</last_name>
    <email>silvia.benemei@unifi.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Careggi Hospital</name>
      <address>
        <city>Florence</city>
        <state>Tuscany</state>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simone Morselli</last_name>
      <phone>3473050852</phone>
      <email>simone.morselli@unifi.it</email>
    </contact>
    <investigator>
      <last_name>Sergio Serni, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mauro Gacci, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrea Liaci, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luca Gemma, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>https://www.amplitude-imaging.com/</url>
    <description>Related Info</description>
  </link>
  <reference>
    <citation>Baria E, Morselli S, Anand S, Fantechi R, Nesi G, Gacci M, Carini M, Serni S, Cicchi R, Pavone FS. Label-free grading and staging of urothelial carcinoma through multimodal fibre-probe spectroscopy. J Biophotonics. 2019 Nov;12(11):e201900087. doi: 10.1002/jbio.201900087. Epub 2019 Aug 13.</citation>
    <PMID>31343832</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 22, 2021</study_first_submitted>
  <study_first_submitted_qc>February 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2021</study_first_posted>
  <last_update_submitted>February 24, 2021</last_update_submitted>
  <last_update_submitted_qc>February 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Florence</investigator_affiliation>
    <investigator_full_name>Simone Morselli</investigator_full_name>
    <investigator_title>PhD Student</investigator_title>
  </responsible_party>
  <keyword>spectroscopy</keyword>
  <keyword>bladder cancer</keyword>
  <keyword>urothelial carcinoma</keyword>
  <keyword>tumor biomarkers</keyword>
  <keyword>metabolomic</keyword>
  <keyword>proteomic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
    <mesh_term>Carcinoma in Situ</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

